Published online before print December 18, 2008

This Article Full Text Full Text (PDF) All Versions of this Article: ajpath.2009.080671v1 174/1/115    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wu, S.-H. Articles by Dong, L. Search for Related Content PubMed PubMed Citation Articles by Wu, S.-H. Articles by Dong, L.

(American Journal of Pathology. 2009;174:115-122.)
© 2009 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.080671

Elevated Expressions of 15-Lipoxygenase and Lipoxin A₄ in Children with Acute Poststreptococcal Glomerulonephritis

Sheng-Hua Wu^*, Pei-Yuan Liao, Pei-Ling Yin, Yong-Mei Zhang^* and Ling Dong^*

From the Department of Pediatrics,^* The First Affiliated Hospital of Nanjing Medical University, Nanjing; the Department of Pediatrics, Central Hospital of Tengzhou, Shandong; and the Department of Pediatrics, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing, China

Anti-inflammatory effects of the 15-lipoxygenase (15-LO) derivatives lipoxin A₄ (LXA₄) and 15-S-hydroxyeicosatetraenoic acid (15-S-HETE) have been documented in many experimental models of acute inflammation. However, the expression levels of 15-LO and its products in human renal diseases remain unknown. This study investigated the expression levels of LXA₄, leukotriene B₄ (LTB₄), and 15-LO in leukocytes and glomeruli obtained from 22 children with acute poststreptococcal glomerulonephritis (APSGN), and determined the modulatory effects of both 15-S-HETE and LXA₄ on LTB₄ synthesis in leukocytes and LTB₄-evoked chemotaxis of polymorphonuclear leukocytes (PMNs) obtained from children during the first 3 days after onset of APSGN. Expression levels of both LXA₄ and 15-LO in leukocytes and glomeruli were up-regulated during the acute phase of disease, further peaking between days 10 and 14, and remained increased after 6 to 8 weeks of APSGN onset. In contrast, blood and urinary levels of LTB₄ as well as the number of glomerular PMNs peaked during the acute phase of disease and then decreased during the resolution phase. Administration of both 15-S-HETE and LXA₄ in vitro inhibited LTB₄-induced chemotaxis of PMNs and production of LTB₄ from leukocytes obtained from patients with APSGN. The current study provides further support for an anti-inflammatory role for 15-LO products in human nephritis through both antagonism and inhibition of leukotriene synthesis and its biological activity.